综述:遗传学在非酒精性脂肪性肝炎精准医疗中的新兴作用
本文综述了NASH遗传学及精准医疗潜力。PNPLA3、TM6SF2、GCKR、MBOAT7和HSD17B13的单核苷酸多态性与NASH发生或进展明确相关,PNPLA3 I148M变异效应较大,与肥胖交互增加肝脂肪和NASH风险。靶向PNPLA3 mRNA敲低在动物模型中减少肝脂肪变、炎症和纤维化。
要点
- PNPLA3、TM6SF2等基因变异与NASH发生进展明确相关。
- PNPLA3 I148M每等位基因约增加2倍NAFLD、3倍NASH和HCC风险。
- 靶向PNPLA3 mRNA敲低在动物模型中减轻肝脂肪变、炎症和纤维化。
核心结论
- NASH遗传学与分子机制的新认识为精准医疗干预铺平道路,可调节特定基因活性。
研究设计与样本
- 综述,通过PubMed检索并纳入相关文献。
主要发现
- PNPLA3、TM6SF2、GCKR、MBOAT7和HSD17B13的单核苷酸多态性与NASH发生或进展明确相关。
- 这些遗传变异常见,对NAFLD、NASH和肝细胞癌发生具有中等至较大效应量。
- PNPLA3 I148M变异每等位基因约增加2倍NAFLD风险、3倍NASH和HCC风险。
- 肥胖与PNPLA3 I148M交互作用,升高肝脂肪含量并增加NASH发生率。
- 在纯合Pnpla3 I148M敲入啮齿类NAFLD模型中,靶向PNPLA3 mRNA敲低减少肝脂肪变、炎症和纤维化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Non-alcoholic steatohepatitis (NASH) is a severe form of non-alcoholic fatty liver disease (NAFLD) characterised by liver fat accumulation, inflammation and progressive fibrosis. Emerging data indicate that genetic susceptibility increases risks of NAFLD, NASH and NASH-related cirrhosis. AIMS: To review NASH genetics and discuss the potential for precision medicine approaches to treatment. METHOD: PubMed search and inclusion of relevant literature. RESULTS: Single-nucleotide polymorphisms in PNPLA3, TM6SF2, GCKR, MBOAT7 and HSD17B13 are clearly associated with NASH development or progression. These genetic variants are common and have moderate-to-large effect sizes for development of NAFLD, NASH and hepatocellular carcinoma (HCC). The genes play roles in lipid remodelling in lipid droplets, hepatic very low-density lipoprotein (VLDL) secretion and de novo lipogenesis. The PNPLA3 I148M variant (rs738409) has large effects, with approximately twofold increased odds of NAFLD and threefold increased odds of NASH and HCC per allele. Obesity interacts with PNPLA3 I148M to elevate liver fat content and increase rates of NASH. Although the isoleucine-to-methionine substitution at amino acid position 148 of the PNPLA3 enzyme inactivates its lipid remodelling activity, the effect of PNPLA3 I148M results from trans-repression of another lipase (ATGL/PNPLA2) by sequestration of a shared cofactor (CGI-58/ABHD5), leading to decreased hepatic lipolysis and VLDL secretion. In homozygous Pnpla3 I148M knock-in rodent models of NAFLD, targeted PNPLA3 mRNA knockdown reduces hepatic steatosis, inflammation and fibrosis. CONCLUSION: The emerging genetic and molecular understanding of NASH paves the way for novel interventions, including precision medicines that can modulate the activity of specific genes associated with NASH.
引用
- Carlsson B, Lindén D, Brolén G, et al. Review article: the emerging role of genetics in precision medicine for patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2020. PMID: 32383295. doi:10.1111/apt.15738
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。